Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Giulia Rivoli, Germana Beltrami, Anna M. Raiola, Carole Paley, Marcello Riggi, Alida Dominietto, Emanuele Angelucci

Blood (2022) 140 (Supplement 1): 13271–13272.

https://doi.org/10.1182/blood-2022-158985

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Haploidentical Allogeneic Hemopoietic Stem Cell Transplant for High Risk Myelodysplastic Syndrome

Anna Maria Raiola, MD, Sara Aquino, MD, Germana Beltrami, MD, Stefania Bregante, MD, Fabio Cruciani, MD, Carmen Di Grazia, MD, Alida Dominietto, MD, Anna Ghiso, MD, Francesca Gualandi, MD, Adalberto Ibatici, MD, Teresa Lamparelli, MD, Carlo Marani, MD, Maria Teresa van Lint, MD, Riccardo Varaldo, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2016) 128 (22): 3173.

https://doi.org/10.1182/blood.V128.22.3173.3173

Published: 2016

Journal Articles

The Prognostic Relevance of Comprehensive Risk Score Is Modulated By Therapy: Analysis of 292 Acute Myeloid Leukemia Patients Registered at the Genova Acute Leukemia Registry (REGAL)

Fabio Guolo, MD, Paola Minetto, MD, Elena Clavio, Giordana Pastori, MD, Daniela Guardo, MD, Lisette Del Corso, MD, Chiara Ghiggi, PhD, Maurizio Miglino, PhD, Germana Beltrami, MD, Angelo Michele Carella, Roberto Massimo Lemoli, MD, Andrea Bacigalupo, MD, Marco Gobbi, MD, Marino Clavio, MD

Blood (2015) 126 (23): 4885.

https://doi.org/10.1182/blood.V126.23.4885.4885

Published: 2015

Journal Articles

The Impact of Comorbidities on Clinical Outcome of Patients with Myelodysplastic Syndromes: A Real-Life Survey

Blood (2014) 124 (21): 4668.

https://doi.org/10.1182/blood.V124.21.4668.4668

Published: 2014

Journal Articles

Interferon-Alpha (IFN-a) Is Able To Maintain Complete Molecular Response (CMR) In Chronic Myeloid Leukemia (CML) Patients Who Maintain Undetectable disease After Imatinib (IM) Discontinuation

Angelo Michele Carella, MD, Germana Beltrami, MD, Chiara Ghiggi, MD

Blood (2013) 122 (21): 5195.

https://doi.org/10.1182/blood.V122.21.5195.5195

Published: 2013

Journal Articles

High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy.

Nicoletta Colombo, Raffaella Grasso, Maurizio Miglino, Marino Clavio, Gianmatteo Pica, MD, Germana Beltrami, Micaela Bergamaschi, Carlo Marani, Antonia Cagnetta, Anna Ghiso, Laura Mitscheunig, Ivana Pierri, Filippo Ballerini, Letizia Canepa, Sara Aquino, Enrico De Astis, Angelo Michele Carella, Marco Gobbi

Blood (2009) 114 (22): 4675.

https://doi.org/10.1182/blood.V114.22.4675.4675

Published: 2009

Journal Articles

Finding of Kinase Domain Mutations at Diagnosis IN PATIENTS with Chronic PHASE Chronic Myeloid Leukemia (CP-CML) MAY Identify Those at High RISK of Disease Progression.

Angelo Michele Carella, Gabriella Cirmena, Gioacchino Catania, Gianmatteo Pica, Germana Beltrami, Alberto Ballestrero, Franco Patrone, Anna Garuti

Blood (2009) 114 (22): 4251.

https://doi.org/10.1182/blood.V114.22.4251.4251

Published: 2009

Journal Articles

Imatinib Achieves High Rates of Complete Citogenetic Remission (CCR) in CML Patients Relapsed after Autografting anf IFN-α Therapy.

Maria T. Corsetti, MD, Germana Beltrami, MD, A.M. Carella, MD

Blood (2004) 104 (11): 4656.

https://doi.org/10.1182/blood.V104.11.4656.4656

Published: 2004

Journal Articles

Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.

Pellegrino Musto, Potito Rosario Scalzulli, Lorella Melillo, Michele Nobile, Matteo Dell’Olio, Antonio La Sala, Saverio Mantuano, Carlo Bodenizza, Antonietta Falcone, Grazia Sanpaolo, Angelo Michele Carella, Michele Mario Greco, Germana Beltrami, Nicola Cascavilla

Blood (2004) 104 (11): 5200.

https://doi.org/10.1182/blood.V104.11.5200.5200

Published: 2004

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Metastatic Breast Cancer.

A.M. Carella, MD, Germana Beltrami, MD, Maria T. Corsetti, MD, Potito Scalzulli, MD, Michele Carella, MD, Roberta Gonella, MD, Alberto Ballestreo, MD, Franco Patrone, MD

Blood (2004) 104 (11): 5129.

https://doi.org/10.1182/blood.V104.11.5129.5129

Published: 2004

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Autografting Is Feasible and Has a Strong Anti Multiple Myeloma Activity.

A.M. Carella, MD, Germana Beltrami, MD, Maria T. Corsetti, MD, Potito Scalzulli, MD, Nicola Cascavilla, MD, Michele Carella, MD, Sandro Nati, MD, Mario M. Greco, MD, Pellegrino Musto, MD

Blood (2004) 104 (11): 5130.

https://doi.org/10.1182/blood.V104.11.5130.5130

Published: 2004

Journal Articles

Long-Term Follow-Up of CML Patients Treated with Autografting Followed by IFN-A and Imatinib for Relapsed Patients.

A.M. Carella, MD, Maria T. Corsetti, MD, Germana Beltrami, MD, Carlo Bodenizza, MD, Marina Cavaliere, MD

Blood (2004) 104 (11): 5217.

https://doi.org/10.1182/blood.V104.11.5217.5217

Published: 2004

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Relapsed/Resistant Hodgkin’s Lymphoma.

Michele Carella, MD, Germana Beltrami, MD, Maria T. Corsetti, MD, Mario M. Greco, MD, Potito Scalzulli, MD, Nicola Cascavilla, MD, Pellegrino Musto, MD, Antonio La Sala, MD, Matteo Dell’Olio, MD, A.M. Carella, MD

Blood (2004) 104 (11): 5135.

https://doi.org/10.1182/blood.V104.11.5135.5135

Published: 2004

NARROW

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Haploidentical Allogeneic Hemopoietic Stem Cell Transplant for High Risk Myelodysplastic Syndrome

The Prognostic Relevance of Comprehensive Risk Score Is Modulated By Therapy: Analysis of 292 Acute Myeloid Leukemia Patients Registered at the Genova Acute Leukemia Registry (REGAL)

The Impact of Comorbidities on Clinical Outcome of Patients with Myelodysplastic Syndromes: A Real-Life Survey

Interferon-Alpha (IFN-a) Is Able To Maintain Complete Molecular Response (CMR) In Chronic Myeloid Leukemia (CML) Patients Who Maintain Undetectable disease After Imatinib (IM) Discontinuation

High WT1 Expression Has An Independent Positive Influence On CR Rate and EFS in Non M3 AML Patients Treated with Chemotherapy.

Finding of Kinase Domain Mutations at Diagnosis IN PATIENTS with Chronic PHASE Chronic Myeloid Leukemia (CP-CML) MAY Identify Those at High RISK of Disease Progression.

Imatinib Achieves High Rates of Complete Citogenetic Remission (CCR) in CML Patients Relapsed after Autografting anf IFN-α Therapy.

Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies.

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Metastatic Breast Cancer.

Reduced Intensity Conditioning Regimen for Allografting Following Autografting Is Feasible and Has a Strong Anti Multiple Myeloma Activity.

Long-Term Follow-Up of CML Patients Treated with Autografting Followed by IFN-A and Imatinib for Relapsed Patients.

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Relapsed/Resistant Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only